Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
From Promise to Therapy
Join The Seattle Genetics Team
We are a group of passionate innovators dedicated to positively impacting the lives of those living with cancer, and we're always looking to add to our team.
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018 More
Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference More
FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma More
Seattle Genetics At A Glance
|Global Headquarters||Bothell, WA|
|Number of Employees||1,000+|
|Clinical & preclinical pipeline programs||12+|
|ADCs in clinical trials using our technology||20+|
Our 4Q/2017 financial results will be announced Feb 6 w/ conf call/webcast at 1:30pm PT/4:30pm ET. Find details… twitter.com/i/web/status/9… · 3 days ago